Human TRAIL/Apo2L, soluble
Slide this table
| Cat-Nr. | 100-301 |
| Size | 50 µg |
| Price | 199 € |
| Source | E. coli |
| Formulation | lyophilized |
| Purity Confirmation | > 98% by SDS-PAGE & HPLC analyses |
| Length [aa] | 168 |
| Molecular Weight | 19.6 kDa |
| Endotoxin Levels | < 0.1 ng/µg of protein (<1EU/µg) |
| Biological Activity | Assay#1: Determined by its ability to induce apoptotic cell death in TRAIL-sensitive U343MG cells. The expected ED50 for this effect is 1.0-3.0 ng/ml. Assay#2: Measured by its ability to induce apoptosis in LN-18 cells (human glioblastoma cells). The expected ED50 for this effect is 0.8 - 2.0 ng/ml. |
| Species Reactivity | Mouse, Human, Bacteria, Chicken |
| Synonyms | TNFSF10; TL2; APO2L; CD253; TRAIL; Apo-2L |
| Description | TRAIL/Apo2L is a cytotoxic protein, which activates rapid apoptosis in tumor cells, but not in normal cells. TRAIL induced apoptosis is achieved through binding to two death-signaling receptors, DR4 and DR5. These receptor types belong to the TNFR superfamily of transmembrane proteins and contain a cytoplasmic "death domain", which activates the cell's apoptotic response. Recombinant human soluble TRAIL/Apo2L is a 168 amino acid polypeptide (19.6 kDa), consisting of the TNF homologous portion of the extracellular domain of the full length TRAIL/Apo2L protein. |
| Protein Sequence | MRERGPQRVA AHITGTRGRS NTLSSPNSKN EKALGRKINS WESSRSGHSF LSNLHLRNGE LVIHEKGFYY IYSQTYFRFQ EEIKENTKND KQMVQYIYKY TSYPDPILLM KSARNSCWSK DAEYGLYSIY QGGIFELKEN DRIFVSVTNE HLIDMDHEAS FFGAFLVG |
| Uniprot ID | P50591 |
| Protein RefSeq | NP_003801.1 |
| mRNA RefSeq | NM_003810.3 |
All prices plus VAT + possible delivery charges